Cytosorbents Investor Relations Material
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. The Company's business strategy is to develop its novel platform technology that enables it to manufacture and sell a broad range of products used in hemodialysis services, emergency medicine, surgery and clinics. The Company’s clinical trials are focused on expanding applications for cytotoxic drugs such as chemotherapy for cancer patients as well as immune cell therapies for autoimmune diseases such as endocrine disorders, infectious disease and immunodeficiencies; regenerative medicine; organ preservation prior to transplantation; tissue repair grafting; acute care stabilization procedures allowing time for surgical interventions; and drug discovery applications for target validation, screening of potential new agents or natural compounds from plants or marine sources.
Key slides for Cytosorbents Corporation
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023
🇺🇸 United States